42 results about "TIMP1" patented technology

In the present invention, the markers identified for liver fibrosis and cirrhosis and the microarray panel thereof comprise at least one of the following proteins/genes:

8 up-regulated genes such as

ANXA2; COL1A2; COL3A1; GSN; LDHB; LUM; PDGFRA and TIMP1.

13 down-regulated genes such as

ALB; ANPEP; APOF; AZGP1; BHMT C8A; CFHR4; CFHR5; COL18A1; FTCD; GYS2; ITIH1, and THRAP1.

9 therapeutic targets such as PDGFRA; S100A4; COL3A1; CCL19; DCN; DPT; APP; TNF; and INFG.

The present invention is capable of screening markers for the early warning of the occurrence for severe fibrosis or cirrhosis and potentially targets for drug design.

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:

• • SPP1, and
  • at least one gene from among A2M and VIM, and
  • at least one gene from among IL8, CXCL10 and ENG, and
  • optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

The invention relates to a kit for early screening and diagnosis of prostate cancer. The kit comprises upstream and downstream primers of at least two genes of ITGB5, TMEM176B and TMP1, wherein an ITGB5 primer pair is as shown in SEQ ID NO:1 and SEQ ID NO:2; a TMEM176B primer pair is as shown in SEQ ID NO:3 and SEQ ID NO:4; a TIMP1 primer pair is shown in SEQ ID NO:5 and SEQ ID NO:6. The kit disclosed by the invention has ultra-high sensitivity and specificity on the prostate cancer, not only can be used for early diagnosis of the prostate cancer, but also can be used for identifying indolent prostate cancers and actively monitoring the progression of prostate cancer diseases.

The invention discloses a reagent for auxiliarily diagnosing lung cancer lymph node metastasis, comprising 8 antibodies which are used for detecting 8 protein markers which are MMP1 (matrix metalloproteinase-1), TIMP1 (tissue inhibitor of metalloproteinases metallopeptidase inhibitor 1), IQGAP1 (IQ motif containing GTPase activating protein 1), TPX2 (targeting protein for Xklp2), uPA (Urokinase-type plasminogen activator), Cathepsin-D, Fascin and pIgR/SC (polymeric immunoglobulin receptor/secretory component). By adopting the 8 antibodies and an immunohistochemical staining result, lung cancer lymph node metastasis can be auxiliarily diagnosed, and the reagent is expected to be used for the risk estimation of lung squamous cell cancer lymph node metastasis and the prognostic prediction. The reagent has high creditability, strong practicability and clinical use value based on the clinical routine immunohistochemical staining technology when the reagent is used for auxiliary diagnosis.

The invention provides a thyroid cancer molecular diagnosis kit. The kit comprises detection reagents for at least three genes of the follows: CK19, survivin, TG, LGALS3, MET, TFF3, SERPINA1, TIMP1, FN1, TPO, TGFA, QPCT, CRABP1, FCGBP, EPS8, PROS1, LRP4, DPP4, GJB3, ST14, EVA1, SPUVE, HBB, MKRN2, MRC2, IGSF1, KIAA0830, RXRG, P4HA2, CDH3, IL13RA1, MTMR4, MDK, CITED1, CHI3L1, ODZ1, N33, SFTPB and SCEL. The benign and malignant of thyroid nodule is judged through the expression level of thyroid cancer tissue specific expression genes, and the operation is simple and convenient.

The invention discloses an antibody composition for detecting pancreatic duct adenocarcinoma immunohistochemical marker protein compositions and application of the antibody composition. The pancreatic duct adenocarcinoma immunohistochemical marker protein compositions comprise TIMP1 and CD82. The antibody composition for detecting the protein compositions comprises monoclonal antibodies of the TIMP1 and monoclonal antibodies of the CD82. The antibody composition and the application have the advantages that the TIMP1/CD82 compositions are used as novel pancreatic duct adenocarcinoma markers, the antibody composition can be widely used in disease identification and diagnosis and prognosis monitoring of pancreatic duct adenocarcinoma, and gaps on immunohistochemical detection in the two aspects can be filled.

The present invention relates to a molecular signature of pigment spots on the skin, comprising the MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2 genes, and various applications of this signature. The invention relates in particular to a method for characterizing an apparent or suspected pigment spot in a human being, which comprises comparison of the levels of expression, in samples of skin taken from said spot and of non-lesioned adjacent skin, of at least one dermal gene related to matrix remodelling or to the extracellular proteoglycan and glycoprotein components thereof, chosen from the list consisting of the MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2 genes. The invention also relates to methods for evaluating the efficacy of a treatment for pigment spots, to cosmetic and therapeutic methods for treating pigment spots, and also to various modulators of said genes and the use thereof.

The genes encoding SCYA2, GADD45B, S100A8, CDKN1A, IL1RL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CHI3L1, SERPINH1, MT1X, KIAA0620, TIMP1, NUMA1, DDIT3 and TOB2, are upregulated in the anterior cingulate of schizophrenic patients compared to normal patients and as such are useful drug targets for schizophrenia. Methods of screening, diagnosing and treating schizophrenia based on these genes are provided. Transgenic nonhuman animals having increased copy number or increased expression levels of these genes are also provided. The transgenic nonhuman animals are used in methods for screening for potential therapeutic agents.

The invention discloses application of one group of serum differential protein combination in preparing a reagent for detecting Alzheimer's disease. The serum differential protein combination is a combination of any three or more than three protein combinations of GSN protein, BDNF protein, TIMP1 protein, VLDLR protein and APLP2 protein. The invention determines the serum differential protein combination which can be used for detecting the Alzheimer's disease. The objectivity, the specificity and the accuracy of the detection can be improved by using the serum differential protein combinationto prepare the reagent for detecting the Alzheimer's disease.

The invention discloses an application of a human epididymal protein 4 in preparation of an NF-[kappa]B agonist. Hypoxia is suggested to be able to induce high expression of renal tubular epithelial cell endogenous HE4. Highly-expressed HE4 induces activation of an NF-[kappa]b pathway to further up-regulate a downstream molecule TIMP1 of NF-[kappa]b so as to promote renal fibrosis. The discovery provides an important enlightenment on the renal fibrosis mechanism and anti-fibrosis treatment.

The invention relates to a detection primer group, a polymerase chain reaction (PCR) detection chip and a detection method for analyzing atherosclerosis related gene expression conditions of human beings and machin. The general atherosclerosis detection primer group for persons and machin comprises amplification primer pairs for respectively amplifying atherosclerosis related genes ACE, APOA1, APOC1, APOF, CCL2, CD40LG, DBP, EDN1, FAS, FASLG, FGG, GLG1, GRN, ICAM1, IL18, IL1beta, IL1RN, IL6, IL6ST, IL8, ITGalpha2beta, ITGalpha4, ITGalpha6, ITGalphaM, ITGalphaV, ITGbeta1, ITGbeta2, LTA, LTB, MTHFR, NFKbeta1, OLR1, PLAUR, PLTP, PON2, SELL, SELP, SELPG, SERPINE1, TIMP1, TNF and TNFRSF1B, and the sequences of the amplification primer pairs are nucleotide sequences shown as SEQ ID NO:1-84. The invention also provides the PCR detection chip containing the primer group and the detection method. The invention can accurately quantify and detect the expression condition of the atherosclerosis related genes of the persons and the machin, and has significance for promotion of basic research of atherosclerosis, prevention detection and clinical treatment.

The present invention is directed to anti-human antibodies recognizing human TIMP1 and the method for making the same. Specifically, the anti-human antibodies are produced using chicken IgY antibodies. The antibodies described herein can be used for the detection and quantification of human TIMP1 protein in patient samples, including bodily fluids, or tissue samples.

Disclosed are methods for predicting, inhibiting, and treating chronic kidney disease (CKD) in a subject that that is preparing to undergo a liver transplant. The methods may include detecting a protein biomarker in a serum sample from the subject prior to the subject being administered a liver transplant procedure and/or after the subject has been administered the liver transplant procedure. Suitable protein markers for the disclosed methods may include but are not limited to osteopontin (OPN) and/or tissue inhibitor of metalloproteases 1 (TIMP1).